Betamethasone 0.06% | Calcipotriene 0.006% | Niacinamide 3%
Betamethasone 0.06% | Calcipotriene 0.006% | Niacinamide 3% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
This compounded topical formulation combines betamethasone 0.06%, calcipotriene 0.006%, and niacinamide 3% for the management of inflammatory, hyperproliferative dermatoses, most commonly psoriasis. Betamethasone provides potent corticosteroid anti-inflammatory activity, calcipotriene inhibits keratinocyte hyperproliferation via vitamin D receptor signaling, and niacinamide (nicotinamide) offers anti-inflammatory, barrier-restoring, and tolerability-enhancing properties. Genesis Compounding prepares this as a prescription-only 503A compounded preparation for patient-specific therapy.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Betamethasone 0.06% | High-potency corticosteroid that suppresses inflammatory mediators, inhibits epidermal hyperproliferation, and provides vasoconstrictive anti-inflammatory activity in psoriatic and eczematous dermatoses. |
| Calcipotriene 0.006% | Synthetic vitamin D₃ analog that binds the vitamin D receptor on keratinocytes and immune cells to inhibit hyperproliferation, promote differentiation, and modulate Th1/Th17 immune dysregulation in psoriasis. |
| Niacinamide 3% | Form of vitamin B₃ with anti-inflammatory, barrier-enhancing, and sebum-reducing properties; also reduces cytokine-mediated inflammation and may improve tolerance to calcipotriene-associated cutaneous irritation. |
Route: Topical application to psoriatic plaques or other inflammatory dermatoses as directed by the prescriber.
- Apply a thin layer to affected areas once or twice daily.
- Avoid facial, axillary, and inguinal application unless specifically prescribed; these sites have enhanced corticosteroid absorption.
- Do not use under occlusion unless directed; this increases both betamethasone and calcipotriene systemic absorption.
- Wash hands after application. Avoid contact with eyes.
Frequency and duration of application are prescriber-determined:
- Typically once to twice daily for the affected area.
- High-potency topical corticosteroids should generally be limited to 2–4 weeks of continuous application; reassessment and tapering are recommended.
- Calcipotriene must be quantity-restricted per prescriber guidance to prevent systemic hypercalcemia.
- Betamethasone: Glucocorticoid receptor agonist; complex translocates to the nucleus, increases expression of anti-inflammatory genes (lipocortin-1), suppresses NF-κB-mediated transcription, reduces prostaglandin and leukotriene synthesis, and exerts anti-mitotic effects on keratinocytes.
- Calcipotriene: Vitamin D receptor (VDR) agonist; downregulates keratinocyte proliferation genes, upregulates differentiation markers, and suppresses Th1/Th17 cytokines (IL-17, TNF-α) implicated in psoriatic inflammation.
- Niacinamide: Inhibits the transfer of melanosomes (melasma-related) and suppresses pro-inflammatory cytokine release from keratinocytes; enhances ceramide and free fatty acid synthesis in the stratum corneum, improving barrier function and reducing irritant-mediated inflammation.
The betamethasone/calcipotriene pairing represents a validated therapeutic approach for plaque psoriasis—targeting different pathophysiological axes simultaneously. Niacinamide 3% is added to enhance barrier function, reduce calcipotriene-associated cutaneous irritation, and provide an additional anti-inflammatory effect.
Prescriber monitoring:
- Monitor serum calcium levels with large-area or prolonged calcipotriene use.
- Evaluate for HPA axis suppression signs (fatigue, hypotension, weight loss) with extended high-potency steroid application.
- Monitor for local adverse effects: skin atrophy, striae, perioral dermatitis, and folliculitis.
- Reassess treatment response and need for continued therapy at 4 weeks.
Contraindications:
- Hypersensitivity to any ingredient
- Hypercalcemia or vitamin D toxicity
- Skin infections at the treatment site
Warnings & Precautions:
- Hypercalcemia: Calcipotriene application over large areas can elevate serum calcium; prescriber should limit weekly quantity and monitor levels.
- Adrenal suppression: Extended high-potency betamethasone use may suppress HPA axis, particularly in pediatric patients or under occlusion.
- Skin atrophy: Prolonged use of betamethasone can produce irreversible skin thinning and striae.
Drug Interactions:
- CYP3A4 inhibitors may increase betamethasone systemic exposure under conditions of enhanced absorption.
- Concurrent systemic vitamin D or calcium supplementation may increase hypercalcemia risk.
Common Side Effects: Application site burning, stinging, dryness (calcipotriene); skin atrophy, telangiectasia (betamethasone); niacinamide is generally well-tolerated at 3% topically.
Store at controlled room temperature (20–25°C / 68–77°F). Protect from light (particularly relevant for calcipotriene). Avoid freezing. Keep container tightly closed. Use before the beyond-use date assigned by Genesis Compounding.
What role does niacinamide play in this psoriasis formula?
Niacinamide (vitamin B₃) provides anti-inflammatory activity, enhances skin barrier function by promoting ceramide synthesis, and may reduce the irritation sometimes associated with calcipotriene. It is a well-tolerated additive that complements the anti-inflammatory and antiproliferative actions of betamethasone and calcipotriene.
How long can I use this cream?
Your prescriber will specify the treatment duration. High-potency corticosteroids like betamethasone are generally limited to 2–4 weeks of continuous use to minimize risks such as skin atrophy and adrenal suppression. Calcipotriene use is also quantity-restricted. Your prescriber may recommend maintenance with a lower-potency regimen after initial therapy.
Why is the betamethasone concentration 0.06% rather than the standard 0.05%?
The 0.06% concentration is a prescriber-determined strength, slightly higher than many commercial formulations, tailored to the patient's therapeutic needs. The pharmacological mechanism is the same regardless of concentration; dose and application frequency are calibrated by the prescriber.
Is this product FDA-approved?
This is a 503A compounded preparation from Genesis Compounding prepared for a specific patient per a prescriber's order. It is not an FDA-approved product. Both betamethasone and calcipotriene are FDA-approved individual agents used in validated dermatologic regimens.
Can I use this on my face?
Generally, high-potency corticosteroids are not recommended for facial use due to the risk of skin atrophy, telangiectasias, and perioral dermatitis. Use on the face only if your prescriber has explicitly directed it and has specified appropriate precautions.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.